Management of tumor lysis syndrome (TLS), a potentially fatal oncologic complication after initiation of chemotherapy or other cytotoxic treatment or occurring spontaneously before treatment, has a significant economic effect. In this retrospective study of hospital administrative data from pediatric and adult patients with laboratory or clinical TLS we found that patients treated with rasburicase, compared with those who received allopurinol, had significantly greater mean reduction in uric acid levels, significantly shorter intensive care unit and overall hospital lengths of stay, and lower total hospitalization costs. Background: The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol. Patients and Methods: This retrospective study of administrative data included hospitalized pediatric and adult patients who had clinical or laboratory TLS and received rasburicase or allopurinol. Each rasburicase-treated patient was propensity score-matched with 4 allopurinol-treated patients. Mean changes in UA within 2 days of treatment initiation were determined. Economic outcomes included mean number of days in the intensive care unit (ICU), total LOS, costs/ hospitalization, and costs/percentage change in UA. Results: Twenty-six rasburicase-treated patients were matched with 104 allopurinol-treated patients. Reduction in plasma UA was 5.3 mg/dL greater for patients treated with rasburicase than for patients treated with allopurinol (P < .0001). Length of ICU stay was 2.5 days less for patients treated with rasburicase than for patients treated with allopurinol (P < .0001), and total LOS was 5 days less for patients treated with rasburicase than for patients treated with allopurinol (P ¼ .02). Total costs per patient were $20,038 lower for patients treated with rasburicase than for patients treated with allopurinol (P < .02). Cost per percentage UA reduction was also lower for patients treated with rasburicase versus patients treated with allopurinol ($3899 vs. $16,894; P < .001). Conclusion: In this analysis of TLS patients who received care in real-world settings, rasburicase versus allopurinol was significantly more effective in treating hyperuricemia and was associated with significantly shorter ICU and overall hospital stays and lower total inpatient costs.
Introduction
Tumor lysis syndrome (TLS) is a potentially fatal oncologic complication characterized by metabolic disturbances consequent to rapid release of nucleotides, proteins, and other contents of tumor cells that have undergone lysis. 1 Most often, TLS follows initiation of chemotherapy or other cytotoxic treatment, but it can occur spontaneously before treatment. 2 It most commonly occurs in certain hematological cancers, particularly non-Hodgkin lymphomas (NHLs) and acute leukemias, but it can also develop in other tumor types, particularly where there is a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy. 3, 4 Tumor lysis syndrome has been defined in terms of laboratory abnormalities and clinical manifestations. Using the definition developed by Cairo and Bishop, 2 a diagnosis of laboratory TLS requires the presence of ! 2 characteristic laboratory abnormalities-hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia-within 3 days before or 7 days after initiation of chemotherapy. Hyperphosphatemia and hyperkalemia consequent to tumor lysis might be exacerbated by renal insufficiency. A review of published case reports and series found that 42 of 105 patients (40%) have received renal replacement therapy, including hemodialysis and peritoneal dialysis. 5 Even when not life-threatening, TLS might require delay administration of chemotherapy or necessitate dose reductions. 6 Management of TLS has a considerable economic effect. In the United States, among patients with hematologic cancers, renal dialysis has been associated with a more than doubling of inpatient length of stay (LOS) and a tripling of costs. 7 In a European analysis, costs in patients with TLS were 11 times higher than in patients with hyperuricemia but no TLS, with increased costs attributable mainly to intensive care unit (ICU) stays. 8 Current management of patients at risk for TLS depends on the individual patient's level of risk defined according to type of malignancy, white blood cell counts, and type of therapy. 1, 3 Allopurinol and its main metabolite reduce uric acid (UA) formation by inhibiting xanthine oxidase, the enzyme catalyzing oxidation of hypoxanthine to xanthine and xanthine to UA. 3, 9 Because allopurinol does not reduce levels of preexisting UA, it might take several days to improve hyperuricemia. 3 Additional limitations of allopurinol include risk of allergic reactions and possible clinically significant interactions with common chemotherapeutic agents. Finally, allopurinol can cause accumulation of xanthine, which can crystallize in the renal tubule, potentially resulting in acute obstructive uropathy. 3 Rasburicase is a recombinant form of urate oxidase, an enzyme endogenous in many nonhuman mammalian species that catalyzes enzymatic oxidation of UA to allantoin. 2, 10 Allantoin is more readily excreted than UA and is 5 to 10 times more soluble. 11, 12 The recombinant molecule carries reduced liability for allergic reactions, including anaphylaxis, that have been associated with nonrecombinant urate oxidase. 10 Unlike allopurinol, rasburicase reduces plasma UA concentrations in patients at high risk of TLS within 4 hours of administration. 13, 14 Rasburicase has also shown superiority to allopurinol in overall antihyperuricemic efficacy, measured according to change in plasma UA concentrations 14 or plasma UA response rates. 13 Reduced need for dialysis with use of rasburicase has been suggested because of lower rates of dialysis in studies of rasburicase-treated patients than in studies of patients not receiving the agent, 15 although no comparative trials designed to evaluate this outcome have been reported. The clinical efficacy of rasburicase notwithstanding, estimated drug acquisition costs (in children, approximately $1575 per day, and in adults, approximately $7690 per day) have led to questions about cost-effectiveness. [16] [17] [18] To address the cost-effectiveness of rasburicase in TLS, we conducted a hospital database analysis of pediatric and adult patients treated for documented TLS. We included in our study a comparison of changes in UA levels and comparisons of duration of ICU care, overall hospital LOS, and costs between patients who were treated with allopurinol and those treated with rasburicase.
Patients and Methods

Study Design and Data Source
This was a retrospective cohort study of administrative data. No institutional board approval was required. For the analysis we used the Cerner Health Facts database. 19 This database captures and stores deidentified, longitudinal electronic health record patient data and then aggregates and organizes these data into data sets to facilitate analysis and reporting. 19 Patient data are obtained from more than 400 US hospital facilities. The database is comprised of patient demographic characteristics, encounters, diagnoses, prescriptions, procedures, laboratory tests, locations of services/patients (eg, ICU), and hospital information and billing data. Clinical records are collected with time-stamped and sequenced information on pharmacy, laboratory, admission, and billing data from all patient care locations.
Patient Selection
All patients of any age who were hospitalized and received rasburicase or allopurinol between January 1, 2005 and March 31, 2009 were initially selected. Patients were required to have clinical or laboratory TLS 5 days before or 2 days after the index hospital admission. Allopurinol-treated patients with a diagnosis of gout (274.x) for inpatient encounters on or within 12 months before first use of allopurinol were excluded. To minimize differences in baseline demographic characteristics between the 2 cohorts, propensity score (PS) matching was used. The PS is defined as the probability of receiving rasburicase versus allopurinol and is calculated from a nonparse logistic regression model that is adjusted for age, gender, tumor type, baseline UA concentration, type of hospital admission (ICU vs. other), ICU admission before the index, Charlson comorbidity index, hospital characteristics, payer type, and other risk factors. Each rasburicase patient was PS-matched with 4 allopurinol patients via a 5:1 digit greedy algorithm. 20 
Outcomes
The effectiveness of rasburicase and allopurinol in treating hyperuricemia was evaluated by determining changes in UA concentrations within 2 days of treatment initiation (ie, the difference between the UA value collected within 1 day before initiating treatment and the last UA value within 2 days after start of treatment). Changes in serum creatinine, potassium, and phosphorous were also evaluated using the same method.
Economic outcomes included mean hospital LOS, mean number of days in the ICU, and total health care costs per hospitalization. Costs per mg/dL change in plasma UA concentration were calculated and compared at the cohort level. Hospital charges were converted to hospital costs by applying a 0.6 cost to charge multiplier, obtained from a Hospital Cost to Charge report from the US Department of Health and Human Services.
Statistical Analysis
Analyses of demographic variables were done using t test for continuous variables and c 2 for categorical variables. Generalized linear models were used to evaluate differences in all outcomes.
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Rasburicase Versus Allopurinol in Treatment of TLS After completion of the analysis, we determined that tumor type was unknown in 40% of patients. Because tumor type can influence severity of TLS and corresponding outcomes, a sensitivity analysis was conducted to determine the effect of missing data on potential parameter estimates for each outcomes assessment. Patients with missing tumor type were initially randomly assigned a tumor type on the basis of the observed distribution of tumor types in patients whose tumor type was known. Statistical assessments across all outcomes were then completed, controlling for the effect of tumor type. Parameter estimates and corresponding P values were then recorded and saved. This process was completed in 1000 iterations, each time recording and saving the parameter estimates. Parameter estimates and their corresponding P values were then ordered, removing the upper and lower 2.5% to establish the 95% confidence interval (CI).
Results
Demographic and Clinical Characteristics
A total of 26 rasburicase-treated patients met inclusion criteria and were matched with 104 allopurinol-treated patients. The 2 groups were comparable in mean age, gender, race, payer type, previous ICU admission, and baseline UA concentration (Table 1) .
In both groups, for a plurality of patients, tumor type was unknown. Distribution of tumor types did not differ significantly between the allopurinol and rasburicase groups: however, in allopurinol-treated patients, more tumors were designated "unknown" (44.3% vs. 34.6% among rasburicase-treated patients). This difference in "unknown" designation was addressed in the sensitivity analysis. Differences in confounders according to group were nonsignificant after matching.
Changes in Plasma UA
At the last available measurement within 2 days of treatment initiation, the mean change of the plasma UA concentration was significantly lower for the rasburicase than for the allopurinol group (Figure 1) , with a 5.3 mg/dL difference between treatment groups (P < .0001). Plasma serum creatinine, potassium, and phosphorus at treatment day 2 did not differ significantly between rasburicase and allopurinol groups ( Table 2) . 2 
Length of Stay and Costs
Mean total length of ICU stay was 2.5 days less among rasburicase-treated patients than among allopurinol-treated patients (P < .0001; Figure 2A ). Mean total hospital LOS was 5 days less for the rasburicase group than for the allopurinol group (P ¼ .02; Figure 2B ).
Total costs per patient were $20,038 lower in rasburicase-treated patients ($34,065) than in allopurinol-treated patients ($54,103; P < .02). As shown in Table 3 , the cost per mg/dL UA reduction was significantly lower for the rasburicase compared with the allopurinol group ($3899 vs. $16,894; P < .001).
There were no TLS directly related deaths in either cohort.
Sensitivity Analyses
To determine the effect of missing tumor type on outcome differences, patients were randomly assigned tumor types on the basis of the distribution of observed tumors. In this iterative process and statistical assessment we concluded that across all assessments, rasburicase patients had consistently favorable changes in UA concentration, reductions in ICU duration, total hospital LOS, and total hospital costs (Table 4) . Differences in total hospital LOS at the upper limit of 95% CI (À3.2 days) and in costs at the lower 
Discussion
We conducted an analysis of matched patients across all age ranges who received rasburicase or allopurinol for treatment of TLS. In our study we found that patients treated with rasburicase exhibited significantly greater reduction in serum UA relative to patients who received allopurinol and that these patients had significantly reduced ICU duration, overall LOS, and total inpatient costs. Cost per percentage of UA reduction was significantly lower for patients treated with rasburicase than for patients treated with allopurinol.
Reductions in UA levels in our analysis were consistent with results of clinical trials of rasburicase in children 14, 21, 22 and adults, 13 with or at risk for TLS, although UA measurement parameters varied among studies. In our analysis, mean UA levels decreased from baseline to day 2 by approximately 76% in rasburicase-treated patients compared with 29% in allopurinol-treated patients. In a trial of 52 children with leukemia or lymphoma, exposure to UA was 2.6-fold less in patients randomized to rasburicase than in those assigned to allopurinol. 14 In a later study of 36 children with hematologic cancers, patients who received rasburicase had a 95% reduction in mean UA levels after 2 days of treatment compared with 41% in patients who received allopurinol. 22 A phase III randomized trial in adults with hematologic malignancies (n ¼ 275) used, as its primary efficacy variable, rates of plasma UA response ( 7.5 mg/dL for all measurements from days 3-7 of treatment) and reported response rates of 87% for rasburicase compared with 66% for allopurinol. 13 In this trial, reduction in plasma UA level from baseline to day 2 was > 85% for rasburicase versus < 20% for allopurinol.
More recently, results on effectiveness of rasburicase against hyperuricemia were reported from a prospective study of children and young adults with advanced mature B-cell NHL who were undergoing cytoreductive chemotherapy, a group at high risk for TLS and renal insufficiency. 21 Patients received at minimum 1 dose of rasburicase 1 day before starting chemotherapy (doses 3 and 2 days before were permitted in already-hyperuricemic patients) followed by optional daily doses for the first 4 days of the chemotherapy. Among 76 evaluable patients, 29 episodes of hyperuricemia (UA > 475.8 mmol/L) were observed in 25 patients. In 25 of 29 episodes (80%), peak daily UA levels normalized within 1 day of rasburicase administration and in all cases levels normalized within 72 hours of rasburicase initiation. Data on comparisons of hospital LOS and costs between patients treated with rasburicase versus those treated with allopurinol have been limited. In a hospital database analysis (n ¼ 126), pediatric patients treated with rasburicase compared with 1:1 matched allopurinol-treated control patients had significantly reduced ICU stays (1.4 vs. 2.5 days; P ¼ .0001). 18 Mean cost per hospitalization was lower for rasburicase-treated patients, but the difference was not statistically significant ($30,470 vs. $35,165; P ¼ .427). Mean hospital LOS was slightly, nonsignificantly lower for patients treated with rasburicase than for those treated with allopurinol (13.8 vs. 14.9 days; P ¼ .69). The results of our current study add to the evidence for improvement in ICU LOS and show significant improvements in hospital LOS and costs not reported in earlier studies. 18 Because of the acquisition costs of rasburicase, health system decision-makers might decide to limit its use to specific patient types. Our results indicate that, from a larger institutional or health system perspective, rasburicase is currently at least cost-effective, and might in fact be cost-saving relative to allopurinol in the broad oncology patient population. The inclusion criteria in our analyses were wide, and patients were not selected on the basis of age, any particular cancer diagnosis, or other characteristic related to degree of risk of TLS.
To reduce drug costs, treatment with rasburicase is often abbreviated and combined with allopurinol. Rasburicase and allopurinol are given concomitantly on day 1 to provide immediate control of UA, and rasburicase is discontinued after 1 to 3 days while allopurinol is continued. 23 The scope of our study did not include use of such combination therapy. However, a recent hospital database analysis reported that combination treatment, although leading to significantly shorter duration of rasburicase therapy (2.1 vs. 2.7 days; P ¼ .0059), was associated with significantly longer mean overall LOS compared with rasburicase monotherapy (15.4 days vs. 10.0 days; P ¼ .0067). 23 There was a trend toward higher hospitalization costs for combination therapy: total cost per hospitalization averaging $46,672 compared with $35,843 for rasburicase alone. Limitations of our study include those inherent to all retrospective observational studies and health care database analyses. Despite methods to correct selection bias and confounding, it is possible that unmeasured confounding variables influenced results. The Health Facts database includes only total costs per hospitalization. Our results suggest that reduced ICU stay and shorter overall LOS were the major drivers of reduced hospitalization costs, but because of this lack of granularity, our analyses could not definitively attribute total cost differences to either of those factors. Moreover, it was not possible to ascertain costs that occurred outside of the hospital. Drug dosing was also beyond the scope of our analyses. Practice guidelines acknowledge clinical trial support for rasburicase regimens that differ from the current US Food and Drug Administration-approved recommended dosing. 3 Future studies on larger populations should yield more definitive data on differences between rasburicase and allopurinol treatment with respect to costs and other outcomes. 
Conclusion
In this retrospective study of hospital administrative data from pediatric and adult patients with laboratory or clinical TLS we found that patients treated with rasburicase, compared with those who received allopurinol, had significantly greater mean reduction in UA levels and significantly shorter ICU and overall hospital LOS, and lower total hospitalization costs. Our analysis indicates that higher drug acquisition costs for rasburicase relative to allopurinol were outweighed by reductions in ICU and hospital LOS, yielding lower overall costs. Future studies should consider differences in outpatient costs when examining the cost-effectiveness of treatment with rasburicase compared with allopurinol.
Clinical Practice Points
Management of TLS has a significant economic effect. Rasburicase versus allopurinol had a significant effect on reduction in plasma UA. Length of ICU stay was significantly less in patients treated with rasburicase versus allopurinol. Cost per percentage of UA production was significantly lower with rasburicase versus allopurinol.
